ASCO2025

Advertisement
Amer Zeidan, MBBS, MHSMyelodysplastic Syndromes | July 16, 2025
The phase 1/2 study's safety and efficacy data on bexmarilimab plus azacitidine for high-risk MDS are promising.
View More
Izzah NawazFollicular Lymphoma | June 13, 2025
Mosunetuzumab’s mechanism of action involves connecting B-cells with T-cells for elimination by the immune system.
Melissa BadamoMyeloma | June 13, 2025
The ratio of T cells to neutrophils at the time of leukapheresis was associated with better outcomes, Dr. Voorhees explained.
Izzah NawazMyeloma | June 11, 2025
Elranatamab shows durable responses and manageable safety in heavily pretreated US patients with myeloma.
Izzah NawazMeeting News | June 11, 2025
Blood clot risk tools may fall short for myeloma patients—study shows aspirin alone might not be enough.
Izzah NawazMeeting News | June 11, 2025
Belantamab may return for RRMM after DREAMM trials show benefit, despite ongoing concerns about eye toxicity.
Andrew MorenoMeeting News | June 11, 2025
The three-arm study enrolled patients with disease refractory to prior carfilzomib, daratumumab, or pomalidomide therapy.
Melissa BadamoMyeloma | June 10, 2025
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
Blood Cancers Today Staff WritersMeeting News | July 1, 2025
AI is revolutionizing oncology with faster analysis, better predictions, and more personalized cancer care.
Ruben A. Mesa, MDMyeloproliferative Neoplasms | July 7, 2025
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Andrew MorenoMeeting News | June 5, 2025
Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL.
Robert ZadottiMantle Cell Lymphoma | June 5, 2025
Ibrutinib plus venetoclax shows strong CR rates and durable remissions in older and younger MCL patients with TP53 mutations.
Robert ZadottiChronic Lymphocytic Leukemia | June 4, 2025
Zanubrutinib and venetoclax show deep and lasting responses in frontline CLL and SLL including those with del 17p or TP53.
Andrew MorenoMeeting News | June 4, 2025
A fixed duration regimen of the combination was compared with a regimen guided by measurable residual disease.
Melissa BadamoFollicular Lymphoma | June 3, 2025
Of 128 efficacy-evaluable patients, the ORR was 80.5% and the CR rate was 74.2% at a median follow-up of 28.3 months.
Melissa BadamoMyelodysplastic Syndromes | June 10, 2025
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
David J. Andorsky, MDChronic Myeloid Leukemia | June 3, 2025
Dr. Andorsky discusses CML dose escalation, treatment discontinuation, and unmet needs in leukemia care.
Advertisement
Advertisement